Imaging Biomarkers of Neuroprotection and Collateral Enhancement Comparing Dosage Tiers
HYPOPERFUSION
A, The enhancement of quantitative cerebral blood volume (qrCBV) in active patients early poststimulation with a dose-response pattern; B, the overall greater penumbral salvage in active vs sham patients; C, the overall greater hypoperfusion lesion (time-to-maximum >6 seconds) reduction in active vs sham patients.In a per-protocol exploratory clinical efficacy analysis, in the active group 3 patients had mRS between 0 and 2 and 2 had mRS of 3 at 90 days. Among the 3 sham patients, 2 had mRS between 0 and 2 and 1 an mRS of 6 at 90 days (eTable 6 in 